ADCsessions in oncology 2023
An overview of recent results and current research on conjugated antibodies across cancer types: breast, lung, genitourinary and digestive. We count with internationally renowned speakers, who will contribute to the meeting with their point of view and experience on the subject.
Format:
ONLINE
Coordinators:
Dr. Eva Ciruelos (University Hospital 12 de Octubre (Madrid), HM Hospitales and Vice President of SOLTI)
Dr. Mafalda Oliveira (Vall d’Hebron Institute of Oncology (Barcelona) and SOLTI Governing Board Member)
16:00 – Welcome by coordinators
16.00 | Welcome
Coordinators (Dr. Eva Ciruelos (University Hospital 12 de Octubre (Madrid), HM Hospitales and Vice President of SOLTI) and Dr. Mafalda Oliveira (Vall d’Hebron Institute of Oncology (Barcelona) and SOLTI Governing Board Member)
16.10 | Overview: breast cancer as an example of innovation in oncology
Dr. Mafalda Oliveira (Hospital Vall d’Hebron/VHIO, Barcelona)
Main clinical results in different tumors:
16:20 | ADCs in breast cancer – Dr. Javier Cortés (International Breast Cancer Center)
16:35 | ADCs in lung cancer – Dr. Rosario Campelo (U.H. a Coruña, Galicia)
16:50 | ADCs in genitourinary cancer – Dr. Guillermo de Velasco (U.H. 12 Octubre, Madrid)
17:05 | ADCs in digestive cancer – Dr. Fernando Rivera (Hospital Marqués de Valdecilla)
17:20 | Response biomarkers and resistance mechanisms
Dr. Leif Ellisen (Massachusetts General Hospital, USA)
17:40 | Round table
Moderated by coordinators
18.10 | Break
18.40 | ADC toxicity
Dr. Aditya Bardia (Massachusetts General Hospital, USA)
Moderator: Dr. Cristina Saura (Hospital Vall d’Hebron/VHIO, Barcelona)
19:00 | Genetic variants and toxicity derived from ADCs
Dr. Rodrigo Sánchez (Hospital 12 de Octubre, Madrid)
Main clinical toxicities in different organs:
19:10 | Round table
Pneumology and ophtalmology experts, one patient and coordinators
19.30 | Conclusions and closure
Coordinators
